William D. Clark

Filings by William D. Clark span 3 companies, the busiest being Vanda Pharmaceuticals Inc., Genocea Biosciences, Inc. and iBio, Inc. Between 7 November 2006 and 10 January 2025, the trades on record add up to 106 filings.

Both buying and selling appear: 6 purchases worth €94k, against 75 sales worth €2.5M. Sales outweigh purchases by €2.4M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 5 share grants and 20 option exercises. So far in 2025, the count stands at 1 purchase and no sales.

A typical purchase (the median) is worth €13k. 1 out of 3 purchases came within 30 days of a purchase by at least one other insider of the same company. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase.

The newest entry dates from 13 January 2025: an open-market purchase of €4,855, in iBio, Inc. The median gap between a trade and its publication by SEC (Form 4) is 1 day. Section 16 rules allow two business days to file each Form 4. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.